JSM2026
Back to all people

kai chen

Eli Lilly and Company
2 appearances in the program

Sessions & presentations

Integrating biomarker discovery and dose-optimization to drive drug development success
Presentation: A Bayesian adaptive enrichment design with historical control for phase II clinical trials
Topic-Contributed Paper Session · Tue, Aug 4 , 4:00 PM
Speaker
Integrating biomarker discovery and dose-optimization to drive drug development success
Presentation: A Bayesian adaptive enrichment design with historical control for phase II clinical trials
Topic-Contributed Paper Session · Tue, Aug 4 , 4:00 PM
Co-Author
↑